|Katherine Vega Stultz|
Katherine Vega Stultz is a results-driven, entrepreneurial leader with a proven track record building world-class organizations. She brings diverse enterprise leadership experience to her role as CEO of Ocelot Bio with expertise that spans across the entire R&D lifecycle. Katherine has made her mark as a corporate leader at several leading global healthcare companies, growing high-performing teams and building brands that have generated over $1B in annual revenue.
Most recently, Katherine served as chief operating officer at Graphite Bio where she successfully advanced the company’s clinical development program. As the company accelerated its efforts to enter the clinic with its lead investigational gene therapy candidate within its first year of launch, Katherine played a pivotal role in spearheading operational management. Her skill as a team builder was evidenced by the rapid expansion of Graphite’s staff – from a team of 10 to more than 60 in less than one year. Previously, Katherine spent 15 years at Celgene Corporation during a period of exponential growth for the company and its products. Ms. Stultz began her career at Eli Lilly & Company and ConvaTec, a Bristol-Myers Squibb company, where she progressed through a series of product development, project management, sales and marketing positions.
Katherine holds a Bachelor of Science degree in Mechanical Engineering (Biomedical Applications) from Cornell University and has attended executive leadership development programs at the Darden School of Business, University of Virginia, IESE Business School in Barcelona, Spain, and the International Institute for Management Development (IMD) in Switzerland.